Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. The purpose of this study is to determine whether apatinib plus chemotherapy drug can improve progression free survival compared with chemotherapy drug in patients with metastatic the non-small cell lung cancer who failed one lines of chemotherapy.
Epistemonikos ID: 50026acb90132d597154bf5897c26cd2143e4c47
First added on: May 21, 2024